文献速递膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌治疗的新型递送系统与药物治疗方法

Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2024-06-06

本文综述了过去5年英文文献与会议摘要,评估非肌层浸润性膀胱癌新型治疗方案的疗效与毒性。帕博利珠单抗、nadofaragene firadenovec及BCG联合N-803已获美国食品药品监督管理局批准用于BCG无应答的原位癌。新型膀胱内递送方案似乎与全身治疗疗效相同且不良事件更少。

要点

  • 帕博利珠单抗、nadofaragene firadenovec及BCG联合N-803已获美国食品药品监督管理局批准用于BCG无应答的原位癌。
  • 五项3期试验正在招募BCG初治的高危非肌层浸润性膀胱癌患者。
  • 新型膀胱内方案似乎与全身治疗疗效相同且不良事件更少。

核心结论

  • 新型药物与器械辅助药物递送系统即将改变非肌层浸润性膀胱癌的治疗。
  • 新型膀胱内方案似乎与全身治疗疗效相同且不良事件更少。

研究设计与样本

  • 综述,检索过去5年发表的英文科学文献与会议摘要。
  • 评估多种新型治疗方案的疗效,关键终点包括复发、进展、总生存、疾病特异性生存和完全缓解。
  • 安全性主要评估为≥3级不良事件的发生率。

主要发现

  • 帕博利珠单抗、nadofaragene firadenovec及BCG联合N-803已获美国食品药品监督管理局批准用于BCG无应答的膀胱原位癌(伴或不伴乳头状肿瘤)。
  • 五项3期试验正在招募BCG初治的高危非肌层浸润性膀胱癌患者。
  • 对于中危非肌层浸润性膀胱癌患者,消融而非辅助治疗的策略受到越来越多的关注。
  • 新型膀胱内方案似乎与全身治疗疗效相同且不良事件更少。

临床怎么用

  • 帕博利珠单抗、nadofaragene firadenovec及BCG联合N-803已获美国食品药品监督管理局批准用于BCG无应答的膀胱原位癌(伴或不伴乳头状肿瘤)。
  • 五项3期试验正在招募BCG初治的高危非肌层浸润性膀胱癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Therapeutic options for patients with non-muscle-invasive bladder cancer (NMIBC) have traditionally been limited to intravesical immunotherapy or chemotherapy. A considerable number of new options have been investigated in recent years. Our aim was to review the efficacy and toxicity of novel therapeutic options (results already reported or currently under investigation) for patients with NMIBC. METHODS: We assessed the efficacy of various novel therapeutic options by examining key endpoints in diverse settings, including recurrence, progression, overall survival, disease-specific survival, and complete response. We identified the principal advantages and limitations for each option. Safety was predominantly evaluated as the incidence of grade ≥3 adverse events. Our investigation focused on evidence from scientific articles and congress abstracts published in English within the past 5 yr. KEY FINDINGS AND LIMITATIONS: To date, pembrolizumab, nadofaragene firadenovec, and the combination of BCG with N-803 have received US Food and Drug administration approval for the treatment of BCG-unresponsive carcinoma in situ of the bladder (with or without papillary tumours). Five phase 3 trials are recruiting BCG-naïve patients with high-risk NMIBC. There is increasing interest in an ablative rather than an adjuvant approach for patients with intermediate-risk NMIBC. CONCLUSIONS AND CLINICAL IMPLICATIONS: Novel drugs and device-assisted drug delivery systems are on the verge of changing the treatment of NMIBC. Novel intravesical options seem to have the same efficacy with fewer adverse events in comparison to systemic therapies. PATIENT SUMMARY: We reviewed new therapy options for non-muscle-invasive bladder cancer. Two agents (pembrolizumab and nadofaragene firadenovec) have been approved to date. Ongoing trials are assessing direct delivery of drugs in solution into the bladder. This route seems to have similar efficacy and fewer side effects than intravenous immunotherapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Guerrero-Ramos F, Boormans JL, Daneshmand S, et al. Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2024. PMID: 38849286. doi:10.1016/j.euo.2024.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。